Elise A Chong, MD

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Perelman Center for Advanced Medicine
3400 Civic Center Blvd
12th Floor, South Pavilion
Philadelphia, PA 19104
Education:
AB (Ecology and Evolutionary Biology )
University of Pennsylvania , 2007.
Non-degree (Graduate courses )
University of Pennsylvania, 2009.
MD (Medical Degree)
Perelman School of Medicine, University of Pennsylvania , 2013.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Farhan A, Chong EA, Schuster SJ, Strelec L, Nasta SD, Landsburg D, Svoboda J.: Bexarotene in Patients With Peripheral T-cell Lymphomas: Results of a Retrospective Study. Clin Lymphoma Myeloma Leuk 19(2): 109-115, Feb 2019.

Chong EA, Svoboda J, Nasta SD, Landsburg DL, Winchell N, Napier E, Mato AR, Melenhorst JJ, Ruella M, Lacey SM, June CH, Schuster SJ.: Sequential Anti CD 19 Directed Chimeric Antigen Receptor Modified T Cell Therapy (CART19) and PD 1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B Cell Non Hodgkin Lymphomas. American Society of Hematology Annual Meeting, San Diego, CA Dec 2018 Notes: "Poster Presentation"

Chong EA, Levine BL, Grupp SA, Davis M, Siegel DL, Maude SL, Gladney WL, Frey NV, Porter DL, June CH, Schuster SJ. : CD 19 Directed CAR T Cell (CTL019) Product Viability and Clinical Outcomes in Non Hodgkin Lymphomas and B Cell Acute Lymphoblastic Leukemia. American Society of Hematology Annual Meeting, San Diego, CA Dec 2018 Notes: "Oral Presentation"

Mato AR, Dorsey C, Chatburn ET, Geoghegan J, Schuster SJ, Svoboda J, Becker PS, Chong EA, Nasta SD, Landsburg DJ, Kennard K, Luning-Prak E, Tsao PS, Hughes ME, Purdom M, Paskalis D, Sportelli P, Miskin HP, Weiss MS, Shadman M. : Phase I/II Study of Pembrolizumab in Combination with TG-1101 (ublituximab) and TGR-1202 (umbralisib) in Patients with Relapsed Refractory CLL or Richter’s Transformation of CLL. American Society of Hematology Annual Meeting, Atlanta, GA Dec 2017 Notes: "Poster Presentation"

Chong EA, Napier E, Svoboda J, Nasta SD, Mato AR, Landsburg DL, Schuster SJ.: Long term outcomes of lenalidomide and rituximab in rituximab resistance patients with indolent B cell and mantle cell lymphomas. American Society of Hematology Annual Meeting, Atlanta, GA Dec 2017 Notes: "Poster Presentation"

Chong EA, Melenhorst JJ, Svoboda J, Nasta SD, Landsburg DJ, Mato AR, Tian L, Parakandi H, Lacey SF, June CF, Schuster SJ.: Phase I/II Study of Pembrolizumab for Progressive Diffuse Large B Cell Lymphoma after Anti-CD19 Directed Chimeric Antigen Receptor Modified T Cell Therapy. American Society of Hematology Annual Meeting, Atlanta, GA Dec 2017 Notes: "Poster Presentation"

Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH.: Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med 377(26): 2545-2554, Dec 28 2017.

Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine BL, June CH, Schuster SJ.: PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood 129(8): 1039-1041, Feb 23 2017.

Schuster SJ, Svoboda J. Nasta S, Chong EA, Porter DL, Landsburg DJ, Mato AR, Bhoj VG, Milone M, Lacey SF, Strelec LE, Zhou AY, Melenhorst JJ, Chew A, Hasskarl J, Wasik MA, Marcucci K, Zheng Z, Levine B, June CH.: Treatment with chimeric antigen receptor modified T cells directed against CD 19 (CTL019) results in durable remissions in patients with relapsed or refractory diffuse large B cell lymphomas of germinal center and non-germinal center origin, "Double Hit" diffuse large B cell lymphomas, and transformed follicular to diffuse large B cell lymphomas. American Society of Hematology Meeting, San Diego, CA Dec 2016 Notes: "Poster Presentation"

Svoboda J, Strelec LE, Landsburg DJ, Nasta SD, Mato AR, Hwang W, Nagle SJ, Chong EA, Garrett S, Waite TS, Napier E, Schuster SJ.: Lenalidomide Maintenance after Autologous Stem Cell Transplant in Patients with High-Risk Relapsed/Refractory Lymphomas Is Feasible and Compares Favorably to Historical Controls: Results of a Phase I/II Trial. American Society of Hematology Meeting, San Diego, CA Dec 2016 Notes: "Poster Presentation"

back to top
Last updated: 03/28/2019
The Trustees of the University of Pennsylvania